Biosimilars set to benefit patients and the NHS
Today marks the European patent expiry for the biologic Adalimumab (Humira), which is prescribed in hospitals for conditions including rheumatoid arthritis, inflammatory bowel disease and psoriasis.
Source: Royal Pharmaceutical Society News - Category: Drugs & Pharmacology Source Type: news
More News: Arthritis | Drugs & Pharmacology | Hospitals | Humira | Inflammatory Bowel Disease | Psoriasis | Rheumatoid Arthritis | Rheumatology